Westbourne Investment Advisors, Inc. Gilead Sciences, Inc. Transaction History

Westbourne Investment Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 22, 2019	SELL	$61.87 - $69.38 $351,730 - $394,425	-5,685 Closed	0 $0
Q1 2019 Apr 15, 2019	SELL	$62.53 - $70.05 $121,433 - $136,037	-1,942 Reduced 25.46%	5,685 $370,000
Q4 2018 Jan 18, 2019	SELL	$60.54 - $79.0 $152,258 - $198,685	-2,515 Reduced 24.8%	7,627 $477,000
Q3 2018 Oct 18, 2018	SELL	$71.28 - $78.92 $68,428 - $75,763	-960 Reduced 8.65%	10,142 $783,000
Q2 2018 Aug 07, 2018	SELL	$64.88 - $75.68 $95,243 - $111,098	-1,468 Reduced 11.68%	11,102 $786,000
Q1 2018 May 08, 2018	SELL	$72.84 - $88.8 $1.26 Million - $1.54 Million	-17,331 Reduced 57.96%	12,570 $948,000
Q4 2017 Jan 31, 2018	SELL	$71.15 - $83.52 $223,126 - $261,918	-3,136 Reduced 9.49%	29,901 $2.14 Million
Q3 2017 Oct 23, 2017	BUY	$72.11 - $85.47 $2.38 Million - $2.82 Million	33,037	33,037 $2.68 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Westbourne Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Westbourne Investment Advisors, Inc. with notifications on news.